SCHEMBL3598200

SCHEMBL3598200

O=C1CCN(CC(O)(c2cn(Cc3ccccc3)c3cc([N+](=O)[O-])ccc23)C(F)(F)F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 1/20 0.38
ACHE P22303 5/20 0.37
ALDH1A1 P00352 5/20 0.37
LMNA P02545 3/20 0.37
BCHE P06276 1/20 0.36
ALOX5 P09917 1/20 0.36
MAOA P21397 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CACNB4 O00305 1/20 0.35
CACNA1A O00555 1/20 0.35
CACNA1G O43497 1/20 0.35
CACNG3 O60359 1/20 0.35
CACNA1F O60840 1/20 0.35
CACNA1H O95180 1/20 0.35
CACNB3 P54284 1/20 0.35
CACNA2D1 P54289 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594430 0.92 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2MAPTTDP1
SCHEMBL3597934 0.91 CACNB4 (0.44) KAT2BALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL13254029 0.90 ALDH1A1 (0.37) KAT2BALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL3595274 0.90 HTR7 (0.39) ACHEALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL3600408 0.90 KCNJ1 (0.47) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL3586209 0.89 ALDH1A1 (0.40) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
Hydrochloric Acid SCHEMBL3593801 0.89 ALDH1A1 (0.37) KAT2BALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL3596441 0.89 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2MAPTTDP1
SCHEMBL3586986 0.89 KDM4E (0.43) ACHEALDH1A1LMNABCHEALOX5
SCHEMBL3596985 0.89 ALDH1A1 (0.40) KAT2BACHEALDH1A1LMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 KAT2B 3394/4885ACHE 3194/4885ALDH1A1 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.